Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
MORPHEUS-UC
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- NCT03869190 ↗
- Terminated
- Hoffmann-La Roche
- Focused
We haven't built an HCP commentary report on MORPHEUS-UC (atezolizumab, enfortumab vedotin and 7 more in Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on MORPHEUS-UC so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 6 | |
| Podcasts | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
- Phase
- Phase 1/Phase 2
- Status
- Terminated
- Conditions
- Urothelial Carcinoma; Bladder Cancer
- Interventions
- Atezolizumab; Enfortumab Vedotin; Niraparib; Magrolimab (Hu5F9-G4); Tiragolumab; Sacituzumab Govitecan; Tocilizumab; Cisplatin; Gemcitabine
- Arms
- Atezolizumab for mUC Cohort (Stage 1) · Active comparator
- Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Niraparib for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Magrolimab for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Tiragolumab for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Tocilizumab for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + RO7122290 for mUC Cohort (Stage 1) · Experimental
- Atezolizumab + Enfortumab Vedotin for mUC Cohort (Stage 2) · Experimental
- Atezolizumab + Sacituzumab Govitecan for mUC Cohort (Stage 2) · Experimental
- Atezolizumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 1 · Active comparator
- Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 1 PD-L1+ Arm 2 · Experimental
- Atezolizumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 1 · Active comparator
- Atezolizumab + Tiragolumab for Cisplatin-ineligible MIBC Cohort 2 PD-L1- Arm 2 · Experimental
- Cisplatin-eligible MIBC Cohort 3 Arm 1 · Active comparator
- Cisplatin-eligible MIBC Cohort 3 Arm 2 · Experimental
- Enrollment
- 272
- Primary outcomes
- Stage 1 mUC Cohorts: Objective Response Rate (ORR)
- MIBC Cohorts: Pathological Complete Response (pCR)
- Sponsor
- Hoffmann-La Roche with Gilead Sciences, Inc., GlaxoSmithKline plc, Seattle Genetics and Astellas
- Start
- Jun 1, 2019
- Primary completion
- Oct 8, 2025
- Results posted
- Yes
- Registry record
- NCT03869190 · updated Aug 3, 2026
Publications
linked from the registry- Drakaki A, Powles T, Bamias A, Martin-Liberal J, Shin SJ, Friedlander T, Tosi D, Park C, Gomez-Roca C, Joly Lobbedez F, Castellano D, Morales-Barrera R, Moreno-Candilejo I, Flechon A, Yuen K, Rishipathak D, DuPree K, Young F, Michielin F, Shemesh CS, Steinberg EE, Williams P, Lee JL. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma). Clin Cancer Res. 2023 Nov 1;29(21):4373-4384. doi: 10.1158/1078-0432.CCR-23-0798. PubMed 37651261